Allogenica
Lyon · Founded 2022
About Allogenica
Allogenica specializes in biotechnology, focusing on the development of allogenic CAR-T cells. These cells are derived from healthy donor hematopoietic stem cells and are bioengineered to express Chimeric Antigen Receptors (CAR) for cancer treatment. This approach aims to provide universal cancer therapies that can be administered to patients without the need for individualized cell harvesting and engineering.
Company Facts
- Founded: 2022
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $2.7M
- Last round: Grant (Mar 2025)
- Website: https://www.allogenica.com
- Phone: [email protected]
Industries & Categories
Analytics, Biopharma, Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/allogenica-3850 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.